Top 5 Hospital Stocks in India Poised for Major Growth in 2025

According to McKinsey's latest report on future of wellness, Gen Zs and millennials are now purchasing more wellness products and services than older generations.

Surprising, isn't it?

It appears, they are prioritizing healthy food and regular exercise, while also taking note of their mental health and stress.

Healthcare is an essential aspect of human life, and its availability and affordability significantly impacts a society's well-being.

The Healthcare Industry in India

The healthcare industry encompasses hospitals, medical devices, medical equipment, clinical trials, telemedicine, outsourcing, medical tourism, health insurance, and more.

The Indian healthcare market, which was valued at US$ 110 billion (bn) in 2016 is now projected to reach US$ 638 bn by 2025.

The healthcare sector, as of 2024, is one of India's largest employers, employing a total of 7.5 million (m) people.

The Indian healthcare sector is witnessing unprecedented growth, with private equity and venture capital investments surpassing US$ 1 bn in the first five months of 2024, marking a 220% increase from the previous year.

In fact, since the past decade, Indian healthcare has transformed itself significantly thanks to advancements in infrastructure, technology, and accessibility.

Digital healthcare initiatives such as CoWIN, e-Sanjeevani, Arogya Setu, e-Hospital, etc. have accelerated progress, enhancing healthcare accessibility and delivery.

Government to the Rescue

With the rising incidence of lifestyle diseases and the escalating costs of healthcare, there is a growing demand for accessible and affordable medical services. Moreover, it's the increasing penetration of health insurance and Government aid that is pushing the growth of the healthcare market.

India's Union Budget 2024-25 emphasised transforming the healthcare sector through increased digital infrastructure and revised health expenditure of US$ 10.7 bn.

The Indian government is planning to introduce a credit incentive programme worth US$ 6.8 billion to boost the country's healthcare infrastructure.

Besides, strategic Government-led initiatives like the National Health Policy, the Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (PM-JAY), and the Ayushman Bharat Digital Mission, have played a pivotal role in shaping the healthcare landscape.

With the healthcare sector gaining momentum, let's look at the top 5 hospital stocks in India poised for major growth in 2025.

#1 Apollo Hospitals Enterprise Ltd.

Apollo Hospitals is Asia's foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including hospitals, pharmacies, primary care and diagnostic clinics, and several retail health models.

The company operates within three segments namely healthcare, diagnostics, and retaildigital health and pharma.

The company has a strong hold on areas like high-end tertiary care specialties - cardiac sciences, oncology, neurosciences, and gastro sciences.

In recent times, one differentiating factor for the company is its occupancy rate, which has risen to 68%, an increase of over 600 basis points on a year-on-year (YoY) basis.

The company's expansion during the first quarter of FY25 was a little lower with 44 new stores opening due to the election season that resulted in a slight delay for approvals.

Their healthcare services business witnessed a strong 15% YoY revenue growth to Rs 26.3 bn. Within this, revenue from insurance patients saw a YoY increase of 17%. This shows there's an increased consumer movement towards high-quality providers.

In healthcare services, the hospital is looking to expand its market boundaries and uncover latent demand through better use of technology and business intelligence tools.

Notably, the Apollo 24/7 digital segment is going to break even within the next 6 to 7 quarters, supported by strong growth in GMV and optimum portfolio mix.

For becoming future ready, the company has a lot on its plate from a futuristic perspective.

Its diagnostic business is poised for strong healthy growth driven by investment in new capacity, expanded test menu, and improved margins.

The hospital is focusing on intensifying efforts to increase surgical volumes at its centers of excellence, supported by an expanded medical team and advanced procedures like CAR T-cell therapy and ZAP-X.

In addition, the hospital is planning to operationalise 4 new hospitals, adding 1,500 beds in key markets. It also has the ambition to operationalise new facilities in Gurgaon, Kolkata, Hyderabad, and Pune within the next 5 quarters.

Here's how the stock price has moved over the past one year -

To know more, check out Apollo Hospitals financial factsheet.

#2 Dr Lal PathLabs

Dr Lal PathLabs is one of India's leading consumer healthcare brands in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services.

One of the company's acquisition - Suburban Diagnostics is scaling up due to the continuous initiatives on franchising and brand communication.

It is also worth noting that the company's Swasthfit brand has contributed to 25% of the total revenue of the enterprise.

Dr Lal Path has deployed AI, data analytics, and machine learning tools to improve patient experience & offer customized solutions. A testament to this is its newly launched website, Reco.ai recommending tests to patients, a logistics app, a wallet, one registration, and Chatbot 2.0.

On the expansion front, the company is setting sights on big buys to expand its foothold in South India.

For the first quarter of FY25, the company achieved a revenue of Rs 6 bn, representing an 11.3% growth over the same quarter last year. This revenue growth was driven by patient volumes, which were at 7.2 m along with 21.1 m samples.

Interestingly, there was a 10.4% increase in the patient numbers in the first quarter of FY25 compared to the fourth quarter of FY24.

Looking ahead, the company's growth trajectory will be driven by the ongoing transition from unorganised to organized sectors, heightened awareness of accurate diagnosis, and emphasis on wellness among others.

Here's how the stock price has performed in the past 1 year -

To know more, check out Lal PathLabs' financial factsheet.

#3 Narayana Hrudayalaya

Narayana Hrudayalaya is engaged in providing economical healthcare services. It has a network of multispecialty and super specialty hospitals spread across multiple locations.

To expand more, the company recently inaugurated a new hospital in Camana Bay.

Recently, the company reported the highest-ever revenue on a quarterly basis on a group level with a sustainable profitability margin.

The company has also entered into the AI segment by launching an AI system which auto creates discharge summaries of patients' stay as an initial step so that the doctors can screen them before giving the final report.

Additionally, the company's digital appointment management system has been revamped and now includes the NH app, the website, queue management, and Kiosks for OPD consultations. In the units where all these systems are deployed, the company is witnessing more than 60% of the consultations being booked digitally, leading to reduced waiting time for patients.

For the first quarter of FY25, the company's consolidated revenue came in at Rs 13,410 m reflecting a growth of 8.7% YoY and 4.8% quarter-on-quarter (QoQ). Narayana Hrudayalaya generated a consolidated EBITDA of Rs 3,274 m at a margin of 24.4% against 23.2% in the same quarter last year.

The management reiterated its aggressive capex plan and commitment towards growing throughput over the next 3-4 years through debottlenecking, refurbishment, and better bed mix.

In the medium term, NARH intends to add 1,500 beds through greenfield expansion across Bengaluru, Kolkata, and Raipur, the benefits of which will be seen from FY29.

More importantly, capex spending would be mainly towards core and high-performing regions such as Bengaluru, Kolkata, and Cayman, to enhance growth visibility.

Here's how the stock price has performed in the past 1 year -

To know more, check out NHL's financial factsheet.

#4 KIMS Hospitals

Krishna Institute of Medical Sciences (KIMS) is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered.

The company offers multidisciplinary healthcare services.

In addition to the multi-specialty hospital and gastro unit at Vizag, KIMS made another acquisition in recent times. Queen's NRI Hospital, a 200-bed hospital at a prime location in Vizag, is expected to help KIMS garner a larger share in the market.

KIMS Hospital also recently inked a MoU with Intuitive for robotic-assisted surgery.

Here are some of the key takeaways from KIMS' Q1 performance (Q1FY25) -

1) The average revenue per operating bed grew by 21.3% and 12.2% on a YoY and QoQ basis, respectively.

2) Average revenue per patient grew by 6.1% and 1.4% on a YoY and a QoQ basis, respectively.

3) IP volumes grew by 7.5% and 7.1% on a YoY and QoQ basis, respectively.

During FY24, KIMS Hospitals clocked a robust performance, posting a consolidated net income of Rs 25.1 bn, which represents a YoY growth of 12.9%. EBITDA for the same period grew by approximately 3.75%.

Here's how the stock price has performed in the past 1 year -

To know more, check out KIMS financial factsheet.

#5 Rainbow Children's Medicare Ltd.

Rainbow Children's Medicare operates multi-specialty pediatric, obstetrics, and gynecology hospital chain in India.

The company offers a wide range of services such as newborn and pediatric intensive care, pediatric multi-specialty services, pediatric quaternary care, obstetrics, and gynecology.

It is the country's largest pediatric hospital chain with 16 hospitals spread across 6 cities.

In July 2024, the Rainbow Children's Hospital launched its Center for Consultations (OPD) in collaboration with Balaji Health Care in Siliguri.

Coming to its financial performance, the company's EBITDA increased by 7% in Q1FY25, reaching Rs 0.9 bn, while the net profit was down by 4.2% to Rs 0.3 bn due to higher depreciation and finance costs.

The company's EBITDA growth has been slightly muted primarily due to the costs associated with its newly opened hospitals.

Rainbow's overall occupancy rate for the quarter was 42.4%, with the matured hospitals achieving 50% occupancy, and the new hospitals, including the recently commissioned hospitals, recording a 27.6% occupancy rate indicating sufficient headroom for growth in the coming quarters.

During the quarter, the company launched a pilot project, the Adult Vaccination Outreach Program (AVON), with the top five vaccine manufacturing companies to cater to the immunisation needs of families.

Going ahead, the company plans to increase the capacity to 2,595 beds by FY27.

Rainbow Children's Medicare is expected to incur Rs 7-7.5 bn in capex over the next three years.

Here's how the stock price has performed in the past 1 year -

To know more, check out Rainbow Children's financial factsheet.

Key Things to Note Before You Invest in Healthcare Stocks

If you are prioritising healthcare industry stocks, it is important to understand the limitations and risks associated.

While healthcare stocks offer stability, they are susceptible to market volatility, regulatory risks, and uncertainties in clinical trials.

Moreover, changes in healthcare policies and regulations can affect the financial performance of healthcare companies.

Additionally, uncertainties in the outcomes of clinical trials can influence the success of new drugs and treatments, impacting investment outcomes.

Despite their defensive characteristics, healthcare stocks can still experience market volatility due to factors like economic conditions and global events.

Therefore, carefully evaluate these factors and consider their potential impact on your financial goals and risk tolerance before you make an investment decision.

Happy Investing!

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...